Aura Biosciences, Inc. (AURA) Stock

Aura Biosciences, Inc. (AURA) is a Healthcare stock trading at $6.33 (as of 2026-06-18), with a market capitalization of $711.30M and a trailing P/E of -3.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aura Biosciences, Inc. is a biotechnology company focused on developing cancer therapies. It works with a virus-like drug conjugate (VDC) platform and develops the VDC candidate AU-011 for ocular oncology, including primary choroidal melanoma and additional indications such as choroidal metastases, and it is based in Cambridge, Massachusetts.

Valuation — source: SEC EDGAR (first-party)
Price$6.33
Market Cap$711.30M
P/E Ratio-3.7
EV / EBITDA-4.9
Price / Book6.18
DCF Value (model)$-21.67
DCF Upside vs Price-442.3%
Profitability & Growth — source: SEC EDGAR
Return on Equity-104.8%
Current Ratio7.09
Valuation vs Sector & Industry
Stock P/E-3.7
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-117.9%
vs Industry-122.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMatrix Capital Management Company, LP ($46.31M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOElisabet de los Pinos
Employees106
CountryUS
IPO Date2021-10-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Palisade Bio, Inc. (PALI)
  • enGene Holdings Inc. (ENGN)
  • Aclaris Therapeutics, Inc. (ACRS)
  • Forte Biosciences, Inc. (FBRX)
  • Relmada Therapeutics, Inc. (RLMD)
  • Avalo Therapeutics, Inc. (AVTX)
  • Crescent Biopharma, Inc. (CBIO)
  • Neurogene Inc. (NGNE)
AURA earnings history · AURA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.